

URETHRA



Hospital Name/Address

**Presbyterian
Hospital of Dallas**
Texas Health Resources

8200 Walnut Hill Lane ☐
Dallas, Texas 75231

Patient Name/Information

Patient name _____ ☐

☐

Medical Record # _____ ☐

☐

Date of Classification _____

Type of Specimen _____

Histopathologic Type _____

Tumor Size _____

DEFINITIONS

Clinical	Pathologic	Primary Tumor (T) (male and female)
☐	☐	TX Primary tumor cannot be assessed
☐	☐	T0 No evidence of primary tumor
☐	☐	Ta Non-invasive papillary, polypoid, or verrucous carcinoma
☐	☐	Tis Carcinoma <i>in situ</i>
☐	☐	T1 Tumor invades subepithelial connective tissue
☐	☐	T2 Tumor invades any of the following: corpus spongiosum, prostate, periurethral muscle
☐	☐	T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, anterior vagina, bladder neck
☐	☐	T4 Tumor invades other adjacent organs
Urothelial (Transitional Cell) Carcinoma of the Prostate		
☐	☐	Tis pu Carcinoma <i>in situ</i> , involvement of the prostatic urethra
☐	☐	Tis pd Carcinoma <i>in situ</i> , involvement of the prostatic ducts
☐	☐	T1 Tumor invades subepithelial connective tissue
☐	☐	T2 Tumor invades any of the following: prostatic stroma, corpus spongiosum, periurethral muscle
☐	☐	T3 Tumor invades any of the following: corpus cavernosum, beyond prostatic capsule, bladder neck (extraprostatic extension)
☐	☐	T4 Tumor invades other adjacent organs (invasion of the bladder)
Regional Lymph Nodes (N)		
☐	☐	NX Regional lymph nodes cannot be assessed
☐	☐	N0 No regional lymph node metastasis
☐	☐	N1 Metastasis in a single lymph node 2 cm or less in greatest dimension
☐	☐	N2 Metastasis in a single node more than 2 cm in greatest dimension, or in multiple nodes
Distant Metastasis (M)		
☐	☐	MX Distant metastasis cannot be assessed
☐	☐	M0 No distant metastasis
☐	☐	M1 Distant metastasis
Biopsy of metastatic site performed ☐ Y ☐ N		
Source of pathologic metastatic specimen _____		

Stage Grouping					Notes
	0a	Ta	N0	M0	Additional Descriptors Lymphatic Vessel Invasion (L) LX Lymphatic vessel invasion cannot be assessed L0 No lymphatic vessel invasion L1 Lymphatic vessel invasion Venous Invasion (V) VX Venous invasion cannot be assessed V0 No venous invasion V1 Microscopic venous invasion V2 Macroscopic venous invasion
	0is	Tis	N0	M0	
		Tis pu	N0	M0	
		Tis pd	N0	M0	
	I	T1	N0	M0	
	II	T2	N0	M0	
	III	T1	N1	M0	
		T2	N1	M0	
		T3	N0	M0	
		T3	N1	M0	
	IV	T4	N0	M0	
		T4	N1	M0	
		Any T	N2	M0	
		Any T	Any N	M1	

Histologic Grade (G)

- ☐ GX Grade cannot be assessed
☐ G1 Well differentiated
☐ G2 Moderately differentiated
☐ G3–4 Poorly differentiated or undifferentiated

Residual Tumor (R)

- ☐ RX Presence of residual tumor cannot be assessed
☐ R0 No residual tumor
☐ R1 Microscopic residual tumor
☐ R2 Macroscopic residual tumor

Additional Descriptors

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- ☐ **m suffix** indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
☐ **y prefix** indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy.
☐ **r prefix** indicates a recurrent tumor when staged after a disease-free interval, and is identified by the “r” prefix: rTNM.
☐ **a prefix** designates the stage determined at autopsy: aTNM.

Prognostic Indicators (if applicable) _____

Staging Support Request: ☐

____ Please fax staging form to my office for completion at fax # _____ ☐

____ Please assign staging form to Dr. _____ ☐

____ I am unable to stage at this time because workup is incomplete. Please return chart to me in 60 days. ☐

Physician initials _____ Date _____

☐
Staging Summary: T _____ N _____ M _____ Stage Group _____

Physician's Signature _____ Date _____